IMVTImmunovant, Inc.

Healthcare
$28.40+63% 1Y

The financials

Immunovant, Inc. by the numbers

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

Immunovant, Inc. income statement, Q1 2027 against the same quarter a year earlier
Income statementQ1 2027Q1 2026Change
Net income−$153M−$121Mn/a
Diluted EPS−$0.75−$0.71n/a

Biotechnology

Ranks #123 of 194 by RyuScore

Compare peers
BLTE-1.9%
Belite Bio, Inc
MANE+0.25%
Veradermics, Incorporated
LGND-1.3%
Ligand Pharmaceuticals Incorporated
RYTM-1.9%
Rhythm Pharmaceuticals, Inc.
KOD+2.2%
Kodiak Sciences Inc.
CGON-1.4%
CG Oncology, Inc.